Date Filed | Type | Description |
09/29/2023 |
8-K
| Bankruptcy or Receivership, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer... |
08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
07/25/2023 |
8-K
| Quarterly results |
07/24/2023 |
8-K
| Quarterly results |
07/14/2023 |
8-K
| Quarterly results |
07/10/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
07/05/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
07/03/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
07/03/2023 |
8-K
| Quarterly results |
07/03/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
06/30/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
06/29/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
06/16/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
06/16/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
06/06/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
06/06/2023 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
03/28/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
03/28/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
03/28/2023 |
8-K
| Quarterly results |
03/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
02/23/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
02/23/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
02/23/2023 |
8-K
| Acquisition/merger/asset purchase announced |
02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 6% stake in Infinity Pharmaceuticals Inc. |
12/30/2022 |
8-K
| Quarterly results |
11/14/2022 |
8-K
| Quarterly results |
11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
08/25/2022 |
8-K
| Other Events Interactive Data |
08/09/2022 |
8-K
| Quarterly results |
08/09/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
07/08/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
06/16/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
06/16/2022 |
8-K
| Quarterly results |
|